New data with daridorexant to be presented at SLEEP 2024
03 juin 2024 01h00 HE
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – June 3, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data with daridorexant, Idorsia’s dual orexin receptor antagonist for the treatment of adults with insomnia,...
New data with daridorexant to be presented at SLEEP 2024
03 juin 2024 01h00 HE
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – June 3, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data with daridorexant, Idorsia’s dual orexin receptor antagonist for the treatment of adults with insomnia,...
Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
31 mai 2024 01h00 HE
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – May 31, 2024 Idorsia Ltd (SIX: IDIA) today announced that data from the Phase 3 study of aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented by Prof....
Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
31 mai 2024 01h00 HE
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – May 31, 2024 Idorsia Ltd (SIX: IDIA) today announced that data from the Phase 3 study of aprocitentan, Idorsia’s endothelin receptor antagonist, will be presented by Prof....
Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
23 mai 2024 01h00 HE
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – May 23, 2024Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting...
Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
23 mai 2024 01h00 HE
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – May 23, 2024 Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting...
Idorsia announces changes to Idorsia Executive Committee and Board of Directors
21 mai 2024 01h00 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Jean-Paul Clozel to retire as CEO and stand for election as Chairman of the Board of DirectorsMathieu Simon to stand for re-election to the Board – taking...
Idorsia announces changes to Idorsia Executive Committee and Board of Directors
21 mai 2024 01h00 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Jean-Paul Clozel to retire as CEO and stand for election as Chairman of the Board of DirectorsMathieu Simon to stand for re-election to the Board – taking...
Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor
21 mai 2024 00h50 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2024. Business highlights ...
Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor
21 mai 2024 00h50 HE
|
Idorsia Pharmaceuticals Ltd
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2024. Business highlights ...